Table: Kyowa Kirin -9-MTH group results (IFRS)
Nov 1 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2021 Sep 30, 2020 Dec 31, 2021
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 253.97 234.00 351.00
(+8.5 pct) (+3.8 pct) (+10.3 pct)
Operating 65.00
(+8.4 pct)
Pretax 41.89 44.18 64.00
(-5.2 pct) (+32.1 pct) (+22.5 pct)
Net 32.91 37.49 50.00
(-12.2 pct) (-33.4 pct) (+6.3 pct)
EPS Basic 61.25 yen 69.80 yen 93.08 yen
EPS Diluted 61.22 yen 69.75 yen
Ann Div 44.00 yen 46.00 yen
-Q2 Div 23.00 yen 22.00 yen
-Q4 Div 22.00 yen 23.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia